Friday, May 1, 2026

North Korea’s Mount Kumgang Could Become a UNESCO World Heritage Site

North Korea's Mount Kumgang is nominated for UNESCO World Heritage status, potentially becoming its third site on the list.

Korean Monks March for Peace: A Spiritual Response to U.S.-Iran Tensions

Buddhist monks will perform ochetoji, advocating for peace in Iran, criticizing U.S. actions and the impact of war on civilians.

North Korea Battles Child Malnutrition With New Nutritional Guides

North Korea is focusing on children's nutrition...

Tag: clinical trials

North KoreaKoreaKimMilitarySouth KoreaAImarketrelationsInternational

Botox Faces New Challenger: Chong Kun Dang’s Toxin Shows Non-Inferiority in China Study

Chong Kun Dang's CKDB-501A shows non-inferiority to Botox in Phase 3 trials for treating glabellar lines, with promising safety data.

Korea Clears New Probiotic Claim: hy’s HY7017 Shows Immune Gains in Human Trials

hy's probiotic strain HY7017 has been approved for immune enhancement, adding to its portfolio of nine recognized ingredients.

NK Cell Cancer Therapies Move Closer to Market as Matica BioLabs Partners With Ingenium

CHA Biotech's Matica BioLabs partners with Ingenium Therapeutics for NK cell therapy production, targeting cancer treatment advancements.

ABL206: First-in-Class Dual Antibody Drug Conjugate Approved for Clinical Trials in the U.S. – What This Means for Cancer Treatment

ABL Bio and Neok Bio received FDA approval for ABL206, a dual-antibody ADC, marking a key milestone in their clinical development efforts.

Is DD01 the Future of MASH Treatment? Insights from D&D Pharmatech’s JP Morgan Presentation

D&D Pharmatech's CEO highlights growth in K-bio at JPM Healthcare Conference, unveiling promising drug data and future plans for clinical trials.

Chong Kun Dang Wins European Phase 1 Approval for Dupixent Biosimilar: Advancing CKD-706’s Global Development

Chong Kun Dang's CKD-706 biosimilar for Dupixent received Phase 1 trial approval in Europe, aiming to expand treatment options for inflammatory diseases.

2026: South Korea’s Advanced Regenerative Medicine R&D Investment Expands – What You Need to Know!

The Ministry of Health and Welfare aims to boost investments in advanced regenerative medicine R&D and improve research infrastructure in South Korea.

HK inno.N’s New Drug K-CAB Applies for U.S. FDA Approval: How Innovative Is the P-CAB Therapy?

HK inno.N's K-Cap for GERD has entered the U.S. approval process, showing superior results in clinical trials over existing treatments.

HLB’s Liragratinib: A Game-Changer in Cholangiocarcinoma Treatment Revealed at ASCO GI 2026!

HLB's lirafugratinib shows promise as a precision oncology drug, targeting FGFR2 in cancer treatment. FDA application expected soon.

Celltrion’s ‘Psoriasis’ Biosimilar Poised to Challenge Big Pharma with Phase 1 Data

The EADV conference in Paris showcased Celltrion's biosimilar CT-P55, confirming its equivalence to Cosentyx in safety and pharmacokinetics.

Celltrion’s Biosimilar Success in Europe Paves the Way for a US Market Takeover

Celltrion's booth at EADV 2025 highlighted biosimilar innovations, showcasing promising clinical trial results and expanding treatment access.

New Obesity Pill Could End Wegovy’s Reign, Offering Faster and Safer Results

Ildong's ID110521156 shows promise as an affordable GLP-1 obesity drug with fewer side effects, aiming to transform the treatment landscape.

Wegovy Gets Stronger: New Dose Promises Even More Weight Loss

Novo Nordisk's new high-dose Wegovy aims to enhance obesity treatment, with promising trial results and a strategic EU rollout planned.

As Wegovy and Mounjaro Soar, Korean Biotechs Seek a Slice of the Obesity Drug Market

South Korean firms are innovating in the GLP-1 obesity treatment market, developing unique drugs to compete with industry leaders.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.